Korro Bio, Inc. Stock Price, News & Analysis

Korro Bio (NASDAQ: KRRO) has reported its full-year 2024 financial results and business updates. The company completed dosing of the first two single ascending dose cohorts in the Phase 1/2a REWRITE clinical study of KRRO-110 for AATD, with no serious adverse events observed. An interim readout is expected in H2 2025.

Financial highlights include: cash position of $163.1 million as of December 31, 2024, expected to fund operations into H2 2026; collaboration revenue of $2.3 million from Novo Nordisk partnership; R&D expenses increased to $63.6 million from $57.2 million in 2023; G&A expenses rose to $30.5 million from $27.3 million; net loss widened to $83.6 million from $81.2 million in 2023.

The company received Orphan Drug Designation for KRRO-110 and is executing its 3-2-1 strategy through 2027, aiming to establish three clinical-stage programs in two tissue types with a single RNA-editing platform. A second development candidate nomination is expected by end of 2025.

Korro Bio (Nasdaq: KRRO) announced that its investigational medicine KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110, the first RNA editing candidate from Korro's OPERA™ platform, is currently in Phase 1/2a REWRITE clinical study.

The company has completed dosing of the first two single ascending dose cohorts in healthy adult volunteers, with an interim readout expected in the second half of 2025. The orphan drug designation, granted for rare diseases affecting fewer than 200,000 people in the US, provides development incentives including tax credits, user fee exemptions, and potential market exclusivity post-FDA approval.

Korro Bio (Nasdaq: KRRO), a clinical-stage biopharmaceutical company specializing in RNA-based genetic medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The event will take place on March 4, 2025, at the Boston Marriott Copley Place.

CEO and President Ram Aiyar, Ph.D. will deliver a presentation at 11:50 a.m. ET, while COO Todd Chappell will engage in one-on-one investor meetings during the conference. Interested parties can access a live webcast of the presentation through Korro's website investor section, with a replay available for 30 days post-event.

Korro Bio has initiated dosing in the REWRITE Phase 1/2a study for KRRO-110, targeting Alpha-1 Antitrypsin Deficiency (AATD). KRRO-110 aims to restore therapeutic M-AAT protein levels using the body's ADAR enzyme. The study will evaluate safety and tolerability in up to 64 participants, including healthy adults and AATD patients.

Interim data from Part 1 is expected in the second half of 2025, with study completion anticipated in 2026. The company is also advancing its pipeline, including a partnered program with Novo Nordisk in a cardiometabolic indication.

Korro's CEO, Ram Aiyar, highlighted the company's evolution to a clinical-stage organization and its strategy to take three product candidates into the clinic over the next three years. For more details, visit ClinicalTrials.gov (NCT06677307).

Korro Bio, a clinical-stage biopharmaceutical company focused on developing genetic medicines through RNA editing, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The event will take place on Monday, January 13, 2025, at 3:45 p.m. PT (6:45 p.m. ET) at the Westin St. Francis in San Francisco.

Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the conference. Other key executives, including Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate.

A live webcast of the presentation will be available on the “Events & Presentations” page in the Investor section of Korro’s website (www.korrobio.com). A replay of the event will be accessible for 30 days following the presentation.

Korro Bio (Nasdaq: KRRO), a clinical-stage biopharmaceutical company developing RNA-based genetic medicines, has announced its participation in four upcoming investor conferences in December 2024. CEO Ram Aiyar will lead fireside chats at the Piper Sandler Healthcare Conference on December 3 and the Evercore ISI HealthCONx Conference on December 4. The company will also participate in Citi's Global Healthcare Conference on December 5 and the Oppenheimer Movers in Rare Disease Summit on December 12, where Dr. Aiyar will join a panel on RNA Editing. CFO Vineet Agarwal and CMO Dr. Kemi Olugemo will attend various sessions and investor meetings across these events.

Korro Bio (Nasdaq: KRRO) has received approval from Australian HREC and TGA clearance to begin a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD). The REWRITE study will evaluate safety, tolerability, and pharmacological aspects of KRRO-110 at various doses. The company plans to dose the first participant in Q1 2025, with an interim readout expected in H2 2025 and study completion in 2026. Previous testing in PiZZ genotype mouse models showed >60% editing and therapeutically relevant levels of functional M-AAT secretion.

Korro Bio (Nasdaq: KRRO) has announced its participation in the Jefferies London Healthcare Conference. CEO and President Ram Aiyar will deliver a presentation on November 19, 2024, at 8:00 a.m. GMT, accompanied by CFO Vineet Agarwal and Chief Medical Officer Kemi Olugemo. The company, which specializes in developing RNA-editing genetic medicines for rare and prevalent diseases, will provide a live webcast of the presentation through their website. A replay will be available for 30 days following the event.

Korro Bio (Nasdaq: KRRO) reported its third quarter 2024 financial results and provided business updates. Significant milestones include the submission of a regulatory filing for the first-in-human clinical study of KRRO-110 for alpha-1 antitrypsin deficiency (AATD), the formation of a Clinical Advisory Board (CAB), and a partnership with Novo Nordisk to develop RNA editing therapies for cardiometabolic diseases. As of September 30, 2024, Korro's cash position was $169.1 million, providing a cash runway into the second half of 2026. R&D expenses increased to $16.0 million from $14.0 million in the same period in 2023, and G&A expenses rose to $7.3 million from $5.1 million. The net loss for the quarter was $21.0 million, compared to $18.5 million in the prior year.